WO2009130198A3 - Hyperglycosylated human coagulation factor ix - Google Patents

Hyperglycosylated human coagulation factor ix Download PDF

Info

Publication number
WO2009130198A3
WO2009130198A3 PCT/EP2009/054707 EP2009054707W WO2009130198A3 WO 2009130198 A3 WO2009130198 A3 WO 2009130198A3 EP 2009054707 W EP2009054707 W EP 2009054707W WO 2009130198 A3 WO2009130198 A3 WO 2009130198A3
Authority
WO
WIPO (PCT)
Prior art keywords
coagulation factor
human coagulation
polypeptides
hyperglycosylated human
hyperglycosylated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2009/054707
Other languages
French (fr)
Other versions
WO2009130198A2 (en
Inventor
Gert Bolt
Claus Kristensen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Priority to US12/937,331 priority Critical patent/US20110137011A1/en
Priority to JP2011505482A priority patent/JP5665733B2/en
Priority to EP09734022A priority patent/EP2268807A2/en
Priority to CN2009801244941A priority patent/CN102105582A/en
Publication of WO2009130198A2 publication Critical patent/WO2009130198A2/en
Publication of WO2009130198A3 publication Critical patent/WO2009130198A3/en
Anticipated expiration legal-status Critical
Priority to US13/723,576 priority patent/US8871714B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The invention relates to hyperglycosylated human coagulation factor IX polypeptides, to processes for preparing said polypeptides, to pharmaceutical compositions comprising said polypeptides and to the use of the compounds for the treatment of diseases alleviated by human coagulation factor IX, in particular, but not exclusively hemophilia.
PCT/EP2009/054707 2008-04-21 2009-04-21 Hyperglycosylated human coagulation factor ix Ceased WO2009130198A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US12/937,331 US20110137011A1 (en) 2008-04-21 2009-04-21 Hyperglycosylated human coagulation factor ix
JP2011505482A JP5665733B2 (en) 2008-04-21 2009-04-21 Highly glycosylated human coagulation factor IX
EP09734022A EP2268807A2 (en) 2008-04-21 2009-04-21 Hyperglycosylated human coagulation factor ix
CN2009801244941A CN102105582A (en) 2008-04-21 2009-04-21 Hyperglycosylated human coagulation factor IX
US13/723,576 US8871714B2 (en) 2008-04-21 2012-12-21 Hyperglycosylated human coagulation factor IX

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08103629 2008-04-21
EP08103629.5 2008-04-21

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/937,331 A-371-Of-International US20110137011A1 (en) 2008-04-21 2009-04-21 Hyperglycosylated human coagulation factor ix
US13/723,576 Continuation US8871714B2 (en) 2008-04-21 2012-12-21 Hyperglycosylated human coagulation factor IX

Publications (2)

Publication Number Publication Date
WO2009130198A2 WO2009130198A2 (en) 2009-10-29
WO2009130198A3 true WO2009130198A3 (en) 2010-05-06

Family

ID=41217185

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/054707 Ceased WO2009130198A2 (en) 2008-04-21 2009-04-21 Hyperglycosylated human coagulation factor ix

Country Status (5)

Country Link
US (2) US20110137011A1 (en)
EP (3) EP2811017A2 (en)
JP (2) JP5665733B2 (en)
CN (1) CN102105582A (en)
WO (1) WO2009130198A2 (en)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2423305A1 (en) * 2006-06-19 2012-02-29 Catalyst Biosciences, Inc. Modified coagulation factor IX polypeptides and use thereof for treatment
AU2008311973B2 (en) * 2007-10-15 2013-10-03 Cangene Corporation Human Factor IX variants with an extended half life
EP4219547A3 (en) 2008-09-15 2023-10-18 uniQure biopharma B.V. Factor ix polypeptide mutant, its uses and a method for its production
UA126265C2 (en) 2010-07-09 2022-09-14 Байовератів Терапьютікс Інк. Factor ix polypeptide and method of its use
CN107190034A (en) * 2010-10-05 2017-09-22 诺沃—诺迪斯克保健股份有限公司 Produce method of protein
TWI595004B (en) 2010-11-03 2017-08-11 介控生化科技公司 Modified ninth factor multi-peptide and use thereof
CA2838833A1 (en) 2011-06-10 2012-12-13 Biogen Idec Ma Inc. Pro-coagulant compounds and methods of use thereof
WO2013016454A1 (en) 2011-07-25 2013-01-31 Biogen Idec Hemophilia Inc. Assays to monitor bleeding disorders
UY34317A (en) 2011-09-12 2013-02-28 Genzyme Corp T cell antireceptor antibody (alpha) / ß
MX365612B (en) * 2012-07-25 2019-06-07 Catalyst Biosciences Inc Modified factor x polypeptides and uses thereof.
US10001495B2 (en) 2012-07-25 2018-06-19 Bioverativ Therapeutics Inc. Blood factor monitoring assay and uses thereof
US9790268B2 (en) 2012-09-12 2017-10-17 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
EA035987B1 (en) * 2012-09-12 2020-09-09 Джензим Корпорейшн Fc CONTAINING POLYPEPTIDES WITH ALTERED GLYCOSYLATION AND REDUCED AFFINITY FOR Fc-GAMMA RECEPTORS
TWI750197B (en) 2012-09-25 2021-12-21 美商百歐維拉提夫治療公司 Methods of using fix polypeptides
CA2888806A1 (en) 2012-10-18 2014-04-24 Biogen Idec Ma Inc. Methods of using a fixed dose of a clotting factor
US10717965B2 (en) 2013-01-10 2020-07-21 Gloriana Therapeutics, Inc. Mammalian cell culture-produced neublastin antibodies
SI3889173T1 (en) 2013-02-15 2023-11-30 Bioverativ Therapeutics Inc. Optimized factor viii gene
CN110256560A (en) 2013-03-11 2019-09-20 建新公司 Site-specific antibody-drug conjugation via glycoengineering
MX380644B (en) * 2013-03-14 2025-03-12 Amgen Inc COMPOSITIONS AND METHODS OF TISSUE INHIBITOR OF METALLOPROTEINASE TYPE THREE (TIMP-3) VARIANTS.
AR095527A1 (en) 2013-03-15 2015-10-21 Biogen Idec Inc FC-FACTOR IX POLYPEPTIDE FORMULATIONS IX
WO2015048330A2 (en) 2013-09-25 2015-04-02 Biogen Idec Ma Inc. On-column viral inactivation methods
KR102245547B1 (en) * 2013-09-30 2021-04-28 얀센 백신스 앤드 프리벤션 비.브이. Method for the clarification of high density crude cell culture harvest
US10584147B2 (en) 2013-11-08 2020-03-10 Biovertiv Therapeutics Inc. Procoagulant fusion compound
US10325687B2 (en) 2013-12-06 2019-06-18 Bioverativ Therapeutics Inc. Population pharmacokinetics tools and uses thereof
DK3083933T3 (en) 2013-12-20 2026-03-16 Biogen Ma Inc USE OF PERFUSION SEEDLING CULTURES TO IMPROVE BIOPHARMACEUTICAL FAT BATCH PRODUCTION CAPACITY AND PRODUCT QUALITY
PL3129067T3 (en) 2014-03-19 2023-05-08 Genzyme Corporation Site-specific glycoengineering of targeting moieties
EA202092926A3 (en) 2014-03-24 2021-10-29 Биовератив Терапьютикс Инк. LYOPHILIZED COMPOSITIONS CONTAINING FACTOR IX
EP3160478A4 (en) 2014-06-30 2018-05-16 Bioverativ Therapeutics Inc. Optimized factor ix gene
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
WO2017011336A1 (en) 2015-07-10 2017-01-19 E.&J. Gallo Winery System and method for dispensing a beverage
BR112018002150A2 (en) 2015-08-03 2018-09-18 Bioverativ Therapeutics Inc factor ix fusion proteins and methods of manufacturing and using them
WO2017136358A1 (en) 2016-02-01 2017-08-10 Bioverativ Therapeutics Inc. Optimized factor viii genes
IL319473A (en) 2016-12-02 2025-05-01 Bioverativ Therapeutics Inc Methods of treating hemophilic arthropathy using chimeric clotting factors
CA3051862A1 (en) 2017-01-31 2018-08-09 Bioverativ Therapeutics Inc. Factor ix fusion proteins and methods of making and using same
TW202545984A (en) 2017-08-09 2025-12-01 美商生物化學醫療公司 Nucleic acid molecules and uses thereof
US11491212B1 (en) 2017-09-27 2022-11-08 Catalyst Biosciences, Inc. Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B
WO2019067766A1 (en) 2017-09-27 2019-04-04 Sigilon Therapeutics, Inc. Methods, compositions, and implantable elements comprising active cells
IL312315A (en) 2018-04-04 2024-06-01 Sigilon Therapeutics Inc Implantable particles and related methods
WO2019195056A1 (en) 2018-04-04 2019-10-10 Sigilon Therapeutics, Inc. Methods, compositions, and implantable elements comprising stem cells
BR112020022164A2 (en) 2018-05-18 2021-02-02 Bioverativ Therapeutics Inc. methods of treating hemophilia a
WO2020033863A1 (en) 2018-08-09 2020-02-13 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof for non-viral gene therapy
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
GB201813528D0 (en) 2018-08-20 2018-10-03 Ucl Business Plc Factor IX encoding nucleotides
UY38389A (en) 2018-09-27 2020-04-30 Sigilon Therapeutics Inc IMPLANTABLE DEVICES FOR CELLULAR THERAPY AND RELATED METHODS
MA55529A (en) 2019-04-03 2022-02-09 Genzyme Corp REDUCED FRAGMENTATION ANTI-ALPHA BETA TCR BINDING POLYPEPTIDES
BR112021020668A2 (en) 2019-04-17 2022-01-11 Codiak Biosciences Inc Exosomes and aav compositions
JP7803014B2 (en) 2019-09-30 2026-01-21 バイオベラティブ セラピューティクス インコーポレイテッド Lentiviral vector formulations
WO2021154414A2 (en) 2020-01-29 2021-08-05 Catalyst Biosciences, Inc. Gene therapy for hemophilia b with a chimeric aav capsid vector encoding modified factor ix polypeptides
US12173307B2 (en) 2020-06-24 2024-12-24 Bioverativ Therapeutics Inc. Methods for the purification of viral vectors
EP4602155A1 (en) 2022-10-11 2025-08-20 Sigilon Therapeutics, Inc. Engineered cells and implantable elements for treatment of disease
JP2025534667A (en) 2022-10-11 2025-10-17 シギロン セラピューティクス， インコーポレイテッド Engineered cells and implantable elements for disease treatment

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020004483A1 (en) * 2000-01-10 2002-01-10 Nissen Torben Lauesgaard G-CSF conjugates
WO2005024006A2 (en) * 2003-09-09 2005-03-17 Novo Nordisk Health Care Ag Coagulation factor vii polypeptides
US20050095668A1 (en) * 2000-10-18 2005-05-05 Maxygen Aps Protein C or activated protein C-like molecules
WO2007111496A1 (en) * 2006-03-28 2007-10-04 Universiteit Utrecht Holding B.V. Improved carbohydrate recognition domains
WO2009051717A2 (en) * 2007-10-15 2009-04-23 The University Of North Carolina At Chapel Hill Human factor ix variants with an extended half life

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3380848D1 (en) * 1982-08-04 1989-12-21 Nat Res Dev Molecular cloning of the gene for human anti-haemophilic factor ix
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5218092A (en) 1988-09-29 1993-06-08 Kyowa Hakko Kogyo Co., Ltd. Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
CN1057534C (en) 1993-08-17 2000-10-18 柯瑞英-艾格公司 Erythropoietin analogs
SK11672002A3 (en) * 2000-01-10 2002-12-03 Maxygen Holdings Ltd. Polypeptide conjugate, method for producing thereof, pharmaceutical composition containing same and its use
DE60138364D1 (en) * 2000-02-11 2009-05-28 Bayer Healthcare Llc CLEANING FACTOR VII OR VIIA CONJUGATE
US20030036181A1 (en) * 2000-06-30 2003-02-20 Okkels Jens Sigurd Peptide extended glycosylated polypeptides
JP4071105B2 (en) * 2000-10-18 2008-04-02 マキシゲン・エイピーエス Protein C or activated protein C-like molecule
US7179617B2 (en) * 2001-10-10 2007-02-20 Neose Technologies, Inc. Factor IX: remolding and glycoconjugation of Factor IX
US20050176108A1 (en) 2003-03-13 2005-08-11 Young-Min Kim Physiologically active polypeptide conjugate having prolonged in vivo half-life
EP2055189A1 (en) * 2003-04-09 2009-05-06 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
ATE469216T1 (en) 2004-08-17 2010-06-15 Csl Behring Gmbh MODIFIED VITAMIN K DEPENDENT POLYPEPTIDES
EP1891231A4 (en) * 2005-05-25 2011-06-22 Novo Nordisk As FACTOR IX GLYCOPEGYL
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
EP2423305A1 (en) * 2006-06-19 2012-02-29 Catalyst Biosciences, Inc. Modified coagulation factor IX polypeptides and use thereof for treatment

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020004483A1 (en) * 2000-01-10 2002-01-10 Nissen Torben Lauesgaard G-CSF conjugates
US20050095668A1 (en) * 2000-10-18 2005-05-05 Maxygen Aps Protein C or activated protein C-like molecules
WO2005024006A2 (en) * 2003-09-09 2005-03-17 Novo Nordisk Health Care Ag Coagulation factor vii polypeptides
WO2007111496A1 (en) * 2006-03-28 2007-10-04 Universiteit Utrecht Holding B.V. Improved carbohydrate recognition domains
WO2009051717A2 (en) * 2007-10-15 2009-04-23 The University Of North Carolina At Chapel Hill Human factor ix variants with an extended half life

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MIMURO J ET AL: "Specific detection of human coagulation factor IX in cynomolgus macaques", JOURNAL OF THROMBOSIS AND HAEMOSTASIS, BLACKWELL PUBLISHING, OXFORD, GB, vol. 2, no. 2, 1 February 2004 (2004-02-01), pages 275 - 280, XP009125189, ISSN: 1538-7933, [retrieved on 20040107] *

Also Published As

Publication number Publication date
JP2011517954A (en) 2011-06-23
EP2268807A2 (en) 2011-01-05
EP2444491A2 (en) 2012-04-25
EP2444491A3 (en) 2012-08-08
CN102105582A (en) 2011-06-22
EP2811017A2 (en) 2014-12-10
US20130095555A1 (en) 2013-04-18
US8871714B2 (en) 2014-10-28
JP5665733B2 (en) 2015-02-04
JP2015038075A (en) 2015-02-26
WO2009130198A2 (en) 2009-10-29
US20110137011A1 (en) 2011-06-09
EP2444491B1 (en) 2016-11-16

Similar Documents

Publication Publication Date Title
WO2009130198A3 (en) Hyperglycosylated human coagulation factor ix
WO2011060049A3 (en) Spiro-oxindole mdm2 antagonists
MY150285A (en) 4-(4-cyano-2-thioaryl)dihydropyrimidinones and their use
TN2011000466A1 (en) Substituted 2-acetamido -5-aryl-1, 2, 4- triazolones and use thereof
WO2011084808A3 (en) Bifunctional polypeptide compositions and methods for treatment of metabolic and cardiovascular diseases
IL209121A (en) Indazolyl derivatives, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for the treatment of inflammatory diseases
WO2009065406A3 (en) Novel cyclic hydrocarbon compounds for the treatment of diseases
WO2009129246A3 (en) Compositions and methods for preparing and using same
WO2012078593A3 (en) Lysophosphatidic acid receptor antagonists and their use in the treatment fibrosis
WO2012058393A3 (en) Dkk1 antibodies and methods of use
WO2011044506A3 (en) Sulphone compounds for use in the treatment of obesity
IL216399A0 (en) Pharmaceutical composition for the treatment of heart diseases
WO2008101985A3 (en) Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization
WO2010130832A3 (en) Amino acid sequences directed against dickkopf-1 and polypeptides comprising the same for the treatment of diseases and disorders associated with bone loss and/or osteolytic lesions
WO2007038459A3 (en) Carboxyamine compounds and their use in the treatment of hdac dependent diseases
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
IL220682A0 (en) 1h-quinazoline-2,4-diones, processes for their manufacture, and use thereof in the preparation of medicaments for treating conditions mediated by the ampa-receptor
WO2008076954A3 (en) Heterocycle compounds and methods of use thereof
WO2007093880A3 (en) Novel pyrone-indole derivatives and process for their preparation
WO2010121164A3 (en) 1,4-benzodiazepinone compounds and their use in treating cancer
WO2009062576A8 (en) Benzimidazoledihydrothiadiazinone derivatives as fructose-1,6-bisphosphatase inhibitors, and pharmaceutical compositions comprising same
WO2011069037A3 (en) Stabilization and storage of biological pharmaceutical compositions
MY150931A (en) Substituted oxazolidinones and their use
WO2011058245A8 (en) Novel mannopyranoside derivatives with anticancer activity
MX2012000954A (en) Pharmaceutical compositions.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980124494.1

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09734022

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2009734022

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2011505482

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 12937331

Country of ref document: US